US · ATAI · BIOTECHNOLOGY
Atai Beckley Inc. (ATAI) intrinsic value and stock valuation
$7.35as of 2026-11-21 · Mkt cap 2.67B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Atai Beckley Inc. DCF and intrinsic value
InvestorsCraft values ATAI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ATAI’s statements →
Atai Beckley Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Dianthus Therapeutics, Inc. (DNTH) $84.55
- Enliven Therapeutics, Inc. (ELVN) $46.53
- Relay Therapeutics, Inc. (RLAY) $16.12
- Amylyx Pharmaceuticals, Inc. (AMLX) $26.02
- Nektar Therapeutics (NKTR) $30.20
- Syndax Pharmaceuticals, Inc. (SNDX) $8.72
- ORIC Pharmaceuticals, Inc. (ORIC) $7.36
- Immatics N.V. (IMTX) $5.77
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.09M | $310K | $310K | $230K | $20.4M |
| Operating income | -$-99.76M | -$-102.69M | -$-125.47M | -$-144.43M | -$-120.33M |
| Net income | -$-660.05M | -$-149.27M | -$-40.22M | -$-152.38M | -$-167.81M |
| EPSd | -$-2.91M | -$-932.01K | -$-253.23K | -$-978.55K | -$-1.04M |
| Operating cash flow | -$-102.67M | -$-82.44M | -$-84.12M | -$-104.47M | -$-63.25M |
| Capital expenditure | -$-900K | -$-100K | -$-590K | -$-1.02M | -$-1.13M |
| Free cash flow | -$-103.58M | -$-82.53M | -$-84.71M | -$-105.49M | -$-64.37M |
| Total assets | $310.5M | $159.4M | $293.5M | $305.4M | $414.2M |
| Total debt | $2.07M | $24.7M | $19.1M | $15.3M | $740K |
| Net debt | -$-83.23M | $7.2M | -$-25.89M | -$-175.27M | -$-361.52M |
| Total equity | $222M | $116.6M | $244.3M | $265.8M | $386M |
| Cash and short-term investments | $256M | $62.3M | $179.3M | $273.1M | $362.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.09M | $310K | $310K | $230K | $20.4M |
| Cost of revenue | $1.01M | $470K | $320K | $170K | $50K |
| Gross profit | $3.08M | -$-170K | -$-10K | $70K | $20.3M |
| Research and development expenses | $53.1M | $55M | $61.9M | $74.1M | $47.9M |
| Selling, general and administrative expenses | $49.8M | $47.5M | $63.6M | $70.4M | $92.8M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $102.8M | $102.5M | $125.5M | $144.5M | $140.7M |
| Cost and expenses | $103.9M | $103M | $125.8M | $144.7M | $140.7M |
| Interest income | $1.48M | $780K | $1.85M | $550K | $200K |
| Interest expense | $1.16M | $3.12M | $2.66M | $920K | $0.00 |
| Depreciation and amortization | $1.01M | $470K | $320K | $170K | $50K |
| Ebitda | -$-657.67M | -$-147.33M | -$-39.9M | -$-150.1M | -$-178.19M |
| Operating income | -$-99.76M | -$-102.69M | -$-125.47M | -$-144.43M | -$-120.33M |
| Total other income/expenses, net | -$-560.09M | -$-48.24M | $82.6M | -$-6.76M | -$-57.91M |
| Income before tax | -$-659.85M | -$-150.93M | -$-42.88M | -$-151.19M | -$-178.23M |
| Income tax expense | $300K | -$-880K | $1.02M | $6.23M | -$-3.99M |
| Net income | -$-660.05M | -$-149.27M | -$-40.22M | -$-152.38M | -$-167.81M |
| Weighted average shares outstanding | $226.5M | $160.2M | $158.8M | $155.7M | $160.7M |
| Weighted average diluted shares outstanding | $226.5M | $160.2M | $158.8M | $155.7M | $160.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $256M | $62.3M | $179.3M | $273.1M | $362.3M |
| Net receivables | $14.4M | $1.35M | $2.26M | $5.63M | $6.32M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $275.7M | $80.1M | $185.6M | $287.1M | $375.1M |
| Property, plant and equipment, net | $4.01M | $3.87M | $2.2M | $1.15M | $150K |
| Goodwill and intangible assets | $11.9M | $3.58M | $1.77M | $0.00 | $0.00 |
| Long-term investments | $900K | $71M | $91.7M | $6.75M | $27.8M |
| Total non-current assets | $34.9M | $79.3M | $107.9M | $18.3M | $39.1M |
| Total assets | $310.5M | $159.4M | $293.5M | $305.4M | $414.2M |
| Accounts payable | $4.91M | $2.62M | $4.59M | $2.4M | $6M |
| Short-term debt | $270K | $9.84M | $280K | $180K | $0.00 |
| Deferred revenue | $1.52M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $23.5M | $25M | $20.1M | $19.9M | $20.9M |
| Long-term debt | $1.8M | $14.9M | $18.9M | $15.2M | $740K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $65.1M | $17.9M | $29M | $19.8M | $7.27M |
| Capital lease obligations | $1.8M | $1.21M | $1.26M | $220K | $0.00 |
| Total liabilities | $88.5M | $42.8M | $49.2M | $39.7M | $28.2M |
| Common stock | $3.63M | $18.8M | $18.6M | $18.6M | $18M |
| Retained earnings | -$-1.36B | -$-700.21M | -$-550.94M | -$-510.19M | -$-357.8M |
| Accumulated other comprehensive income (loss) | -$-20.93M | -$-18.47M | -$-19.46M | -$-21.7M | -$-8.34M |
| Total equity | $222M | $116.6M | $244.3M | $265.8M | $386M |
| Total investments | $171.6M | $115.8M | $225.9M | $89.3M | $27.8M |
| Total debt | $2.07M | $24.7M | $19.1M | $15.3M | $740K |
| Net debt | -$-83.23M | $7.2M | -$-25.89M | -$-175.27M | -$-361.52M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-660.05M | -$-150.05M | -$-43.9M | -$-157.42M | -$-174.24M |
| Depreciation and amortization | $1.01M | $470K | $320K | $170K | $50K |
| Stock-based compensation | $0.00 | $25.5M | $33M | $42.4M | $63.4M |
| Change in working capital | -$-6.47M | -$-9.2M | $7.47M | -$-3.33M | -$-7.6M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.7M | -$-1.87M | $2.14M | -$-3.03M | $2.3M |
| Net cash provided by operating activities | -$-102.67M | -$-82.44M | -$-84.12M | -$-104.47M | -$-63.25M |
| Investments in property, plant and equipment | -$-10.87M | -$-100K | -$-260K | -$-770K | -$-1.13M |
| Acquisitions, net | $4.64M | $360K | -$-440K | $0.00 | -$-52.94M |
| Net cash used for investing activities | -$-109.13M | $59.2M | -$-53.3M | -$-86.85M | -$-81.28M |
| Common stock issued | $283.4M | $540K | $0.00 | $0.00 | $409.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $269.5M | $5.37M | -$-8.36M | $20.8M | $409.9M |
| Net change in cash | $57.8M | -$-17.53M | -$-145.58M | -$-171.65M | $265M |
| Cash at end of period | $85.3M | $27.5M | $45M | $190.6M | $362.3M |
| Operating cash flow | -$-102.67M | -$-82.44M | -$-84.12M | -$-104.47M | -$-63.25M |
| Capital expenditure | -$-900K | -$-100K | -$-590K | -$-1.02M | -$-1.13M |
| Free cash flow | -$-103.58M | -$-82.53M | -$-84.71M | -$-105.49M | -$-64.37M |
Line items
Line items
Line items
About Atai Beckley Inc.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
- CEO
- Srinivas G. Rao
- Employees
- 99
- Beta
- 1.57
Explore
Frequently asked questions
What is the intrinsic value of Atai Beckley Inc. (ATAI)?
Atai Beckley Inc. (ATAI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ATAI undervalued?
ATAI trades at a price of $7.35 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.